PharVision Advisers’s Cosan CSAN Stock Holding History

PharVision Advisers’s Portfolio CSAN Stock Details CSAN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-58,136	Closed	-$230K	–	233
2025 Q4	$230K	Buy	58,136 +23,985	+70%	+$109K	0.12%	446
2025 Q3	$157K	Buy	+34,151	New	+$158K	0.09%	560

Other funds holding CSAN

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Aquamarine Financial George Town $1.37B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

MCM

Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return

PharVision Advisers's CSAN Position: Q1 2026 in Review

PharVision Advisers sold out of Cosan (CSAN) in Q1 2026, closing a stake of 58,136 shares — an estimated $230K sold.

PharVision Advisers first reported a position in CSAN in Q3 2025 and held it in 2 quarters. The position peaked at $230K in Q4 2025. 74 funds tracked by Wall St. Rank hold CSAN as of Q1 2026.

PharVision Advisers reported no remaining Cosan position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 58,136 Cosan shares in Q1 2026, an estimated $230K.
PharVision Advisers first reported a position in Cosan in Q3 2025 and held it in 2 quarters.
PharVision Advisers's Cosan position peaked at $230K in Q4 2025.
74 funds tracked by Wall St. Rank held Cosan as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.